The home shopping channel violated a previous final order prohibiting QVC from using deceptive advertising practices to market weight-loss products, the FTC alleges in a March 24 complaint filed in Eastern Pennsylvania federal court. The commission maintains each airing of programs for Bee-Alive, For Women Only, Lipofactor Cellulite Target Lotion and Lite Bites a violation of the previous order. Programs touted testimonials from patients with cancer, lupus and multiple sclerosis who also claimed to have lost between 30 lbs and 140 lbs. In a same-day 1release, FTC points out the "claims for these products are not only unsubstantiated, but for some, scientifically impossible." Agency seeks monetary civil penalties, consumers redress and to permanently enjoin the Comcast subsidiary from violating the June 2000 order...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.
Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.
The verdict by the Unified Patent Court in the dispute between Sanofi/Regeneron Pharmaceuticals and Amgen explains what companies should look out for when deciding whether infringement has taken place when it comes to second medical use patents.
